Evidence map›Paper›PMID 37443766›Full record

ArticleCells2023

ABCB5+ Limbal Epithelial Stem Cells Inhibit Developmental but Promote Inflammatory (Lymph) Angiogenesis While Preventing Corneal Inflammation.

Berbang Meshko, Thomas L A Volatier, Karina Hadrian, Shuya Deng, Yanhong Hou, Mark Andreas Kluth, Christoph Ganss, Markus H Frank, Natasha Y Frank, Bruce Ksander and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Berbang MeshkoDepartment of Ophthalmology, University of Cologne, 50937 Cologne, Germany.ORCID 0009-0007-3646-3823
Thomas L A VolatierDepartment of Ophthalmology, University of Cologne, 50937 Cologne, Germany.ORCID 0000-0002-3519-1359
Karina HadrianDepartment of Ophthalmology, University of Cologne, 50937 Cologne, Germany.ORCID 0000-0001-9713-1477
Shuya DengDepartment of Ophthalmology, University of Cologne, 50937 Cologne, Germany.
Yanhong HouDepartment of Ophthalmology, University of Cologne, 50937 Cologne, Germany.
Mark Andreas KluthTICEBA GmbH, Im Neuenheimer Feld 517, 69120 Heidelberg, Germany.ORCID 0000-0003-0764-4645
Christoph GanssTICEBA GmbH, Im Neuenheimer Feld 517, 69120 Heidelberg, Germany.
Markus H FrankTransplant Research Program, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-1312-0488
Natasha Y FrankHarvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA.
Bruce KsanderMassachusetts Eye & Ear Infirmary, Schepens Eye Research Institute, Boston, MA 02114, USA.
Claus CursiefenDepartment of Ophthalmology, University of Cologne, 50937 Cologne, Germany.ORCID 0000-0002-1958-411X
Maria NotaraDepartment of Ophthalmology, University of Cologne, 50937 Cologne, Germany.
University of Cologne · DEEdith Cowan University · AURheacell (Germany) · DEMassachusetts Eye and Ear Infirmary · US

Funding

Stem Cell Integral Membrane Transporter ABCB5 and Dermal RegenerationP01AG071463 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI GEORGE F MURPHY · 2022 to 2026
$13.6M
ABCB5-positive stem cells for LSCD therapyR01EY025794 · NEI · BOSTON CHILDREN'S HOSPITAL · PI NATASHA Y FRANK, Markus H. Frank · 2016 to 2026
$6.1M
Multipotent ABCB5-positive cell therapeutics for corneal diseaseR24EY028767 · NEI · BRIGHAM AND WOMEN'S HOSPITAL · PI FRANK, MARKUS H., FRANK, NATASHA Y · 2018 to 2022
$5.9M
Skin-Intrinsic Immunosuppressive Mesenchymal Stem Cells and aGVHDR01HL161087 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FRANK, MARKUS H., FRANK, NATASHA Y · 2022 to 2025
$1.7M
NEI NIH HHS R01 EY025794NEI NIH HHS R24 EY028767NHLBI NIH HHS R01 HL161087NIA NIH HHS P01 AG071463
6 · The paper itself

Abstract

The limbus, the vascularized junction between the cornea and conjunctiva, is thought to function as a barrier against corneal neovascularization. However, the exact mechanisms regulating this remain unknown. In this study, the limbal epithelial stem cell (LESC) marker ABCB5 was used to investigate the role of LESCs in corneal neovascularization. In an ABCB5KO model, a mild but significant increase of limbal lymphatic and blood vascular network complexity was observed in developing mice (4 weeks) but not in adult mice. Conversely, when using a cornea suture model, the WT animals exhibited a mild but significant increase in the number of lymphatic vessel sprouts compared to the ABCB5KO, suggesting a contextual anti-lymphangiogenic effect of ABCB5 on the limbal vasculature during development, but a pro-lymphangiogenic effect under inflammatory challenge in adulthood. In addition, conditioned media from ABCB5-positive cultured human limbal epithelial cells (ABCB5+) stimulated human blood and lymphatic endothelial cell proliferation and migration. Finally, a proteomic analysis demonstrated ABCB5+ cells have a pro(lymph)angiogenic as well as an anti-inflammatory profile. These data suggest a novel dual, context-dependent role of ABCB5+ LESCs, inhibiting developmental but promoting inflammatory (lymph)angiogenesis in adulthood and exerting anti-inflammatory effects. These findings are of high clinical relevance in relation to LESC therapy against blindness.

Indexed as

Corneal NeovascularizationKeratitisLimbus CorneaeAdultAnimalsATP Binding Cassette Transporter, Subfamily BHumansInflammationMiceProteomicsStem CellsABCB5 protein, humanABCB5 protein, mouseATP Binding Cassette Transporter, Subfamily BABCB5cornealimbal epithelial stem cells(lymph)angiogenesis

Identifiers

PMID37443766
PMCPMC10341195
OpenAlexW4382403067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.